1-7 of 7
Authors: Nancy Dezutter
Journal Article
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial
Clinical Infectious Diseases, Volume 79, Issue 4, 15 October 2024, Pages 1088–1098, https://doi.org/10.1093/cid/ciae365
Published: 05 August 2024
Journal Article
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons
Clinical Infectious Diseases, Volume 78, Issue 6, 15 June 2024, Pages 1732–1744, https://doi.org/10.1093/cid/ciae010
Published: 22 January 2024
Journal Article
1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.2467, https://doi.org/10.1093/ofid/ofad500.2467
Published: 27 November 2023
Journal Article
LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
Open Forum Infectious Diseases, Volume 9, Issue Supplement_2, December 2022, ofac492.1868, https://doi.org/10.1093/ofid/ofac492.1868
Published: 15 December 2022
Journal Article
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
The Journal of Infectious Diseases, Volume 227, Issue 6, 15 March 2023, Pages 761–772, https://doi.org/10.1093/infdis/jiac327
Published: 29 July 2022
Journal Article
119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated
Open Forum Infectious Diseases, Volume 7, Issue Supplement_1, October 2020, Pages S187–S188, https://doi.org/10.1093/ofid/ofaa439.429
Published: 31 December 2020
Journal Article
121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic
Open Forum Infectious Diseases, Volume 7, Issue Supplement_1, October 2020, Pages S188–S189, https://doi.org/10.1093/ofid/ofaa439.431
Published: 31 December 2020
